You can buy or sell ADMP and other stocks, options, ETFs, and crypto commission-free!
Adamis Pharmaceuticals Corporation Common Stock, also called Adamis Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. Read More The company was founded in June 2006 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Adamis Pharmaceuticals: Refused, Accepted, Missed, And Predictable
The company released a positive press release about the milestone achieved in 2018, but a thorough reading of the 10-K was required to find out that the company is in a legal battle with Belcher Pharmaceuticals over an epinephrine patent.
Adamis Pharmaceuticals Corp.
Adamis Pharmaceuticals Corp. shares surged in the extended session Wednesday after the biotech company said its partner Sandoz Inc. launched an alternative to epinephrine auto-injectors like Mylan NV's EpiPen. Adamis shares rallied 14% after hours, after closing up 4.8% at $2.63 in regular trading Wednesday. Adamis said that Sandoz, which is part of Novartis AG , launched Symjepi, a single-dose treatment for allergic reactions including anaphylaxis. "With recent news of epinephrine product shortages in the ...
Markets InsiderMar 14
Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration ("FDA”) has accepted for review the company’s New Drug Application ("NDA”) for its higher naloxone injection product candidate for the treatment of opioid overdose.
-$0.19 per share
-$0.28 per share